Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to... see more

TSXV:SBM - Post Discussion

Sirona Biochem Corp > Insight from Germany WO
View:
Post by biorun on Jun 21, 2022 3:38pm

Insight from Germany WO

Here is an interesting insight folks to digest. The future looks exceptionally bright.

From @ Matrix - german board. 
---------------------------
 Interesting. The share rises by 100%, then corrects a little and the skeptics come forward. Just to make it clear to everyone: this is a SMALL CAP. And for such a person, the latest reports were/are extremely positive. Of course, it's a shame they didn't get financial details on the AbbVie deal, but I think it's a good deal that puts Sirona in a new league. And the tweet from the BIO shows that Linda Pullan is likely to take on a more sustainable role. Dr. Bieber is indeed quite old. However, I see more opportunities than risks in personnel matters. Someone with this experience can do Sirona good, because there is a lack of structures and processes. Maybe someone here has seen the film "You never stop learning" - in my opinion, it was beautifully presented. Bringing seniority in will help and I think it can do some positive things especially at TFChem. In addition, it is conceivable that Dr. Bieber still has relevant contacts with Bayer - which could definitely be exciting. With AbbVie as a partner, it will now be easier to approach and convince other prospects. This also applies to investors, because in my opinion Sirona urgently needs a different shareholder structure. Now I'm curious to see how Animal Health and Anti-Aging will continue. These are the two projects where I see the most potential in the coming weeks. With anti-aging in particular, it would be nave to assume that this project doesn't already have AbbVie's attention. If there is a clinical study and it is convincing, Sirona should quickly receive a takeover bid from AbbVie. Sirona currently has a market value of EUR 52 million - for "Big Pharma" that's "pocket money". That's extremely low - especially in the context of the deal - and I'm pretty sure that new buyers will appear here soon - especially if more positive news comes. There will also be a new CEO update coming soon. I'm curious what the management changes in Canada will look like. I think it is quite likely that a possible larger institutional investor will insist on a permanently different corporate governance. Specifically: Dr. In my opinion, Verrico will not (be able to) remain CEO and remain on the board. A new CEO is obvious. And then just an uplisting. We will see. m@trix
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities